Drugs / IPG7236
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05288543 | Apr 2022 → Mar 2023 | atopic eczema | Nanjing Immunophage Biotech Co., Ltd | Terminated | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT07508761 | Jun 2026 → Dec 2028 expected | neoplasm | Nanjing Immunophage Biotech Co., Ltd | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05142592 | Nov 2021 → Feb 2026 | — | Nanjing Immunophage Biotech Co., Ltd | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IPG7236 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05142592 ↗ |
| Route | Oral | “IPG7236 administered orally as a single agent” NCT05142592 ↗ |